Massimo Di Maio

Q: What Schools Are Affiliated With Massimo Di Maio

Massimo Di Maio is affiliated with the following schools: University of Milan, University of Verona, University of Palermo, University of Turin, University of Bologna

Massimo Di Maio's AcademicInfluence.com Rankings

Massimo Di Maio

Computer Science

#9607

World Rank

#10083

Historical Rank

Machine Learning

#4252

World Rank

#4301

Historical Rank

Artificial Intelligence

#4603

World Rank

#4665

Historical Rank

Database

#6576

World Rank

#6811

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Massimo Di Maio's Degrees

PhD Computer Science University of Milan
Bachelors Information Technology University of Bologna

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026
Fastest Accelerated Online Bachelor's of Information Technology 2025
Best Online Bachelor’s in Information Technology for 2025

Why Is Massimo Di Maio Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Massimo Di Maio's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma (2008) (920)
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. (2005) (447)
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. (2012) (349)
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. (2014) (322)
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. (2015) (322)
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. (2010) (294)
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. (2005) (289)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. (2006) (263)
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. (2012) (233)
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials (2005) (200)
Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. (2005) (194)
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. (2011) (181)
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. (2009) (180)
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective (2020) (173)
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. (2009) (173)
Patient-reported outcomes in the evaluation of toxicity of anticancer treatments (2016) (168)
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study (2004) (166)
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. (2004) (152)
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. (2015) (136)
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. (2015) (128)
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life (2007) (127)
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer (2004) (126)
Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles (2016) (123)
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. (2010) (113)
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. (2016) (112)
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. (2011) (111)
Papillary renal cell carcinoma: A review of the current therapeutic landscape. (2015) (100)
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. (2013) (99)
Patients’ perception of chemotherapy side effects: Expectations, doctor–patient communication and impact on quality of life – An Italian survey (2017) (99)
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis (2015) (97)
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. (2014) (94)
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. (2007) (93)
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. (2016) (93)
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. (2016) (91)
Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. (2007) (90)
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study (2006) (89)
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. (2020) (86)
Quality of Life in elderly patients with cancer (2003) (86)
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. (2009) (82)
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. (2020) (78)
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. (2010) (77)
Second-Line Treatment of Advanced Non-small Cell Lung Cancer (2008) (73)
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis (2019) (73)
Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. (2012) (73)
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. (2010) (71)
Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial (2019) (69)
Hepatocellular Carcinoma: Systemic Treatments (2002) (68)
Is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery? (2011) (68)
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. (2011) (67)
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. (2018) (66)
A review of guidelines for lung cancer. (2018) (65)
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study (2017) (64)
Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. (2015) (63)
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy (2021) (63)
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study (2006) (63)
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. (2014) (62)
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. (2016) (60)
Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. (2010) (59)
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (2018) (58)
Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. (2015) (57)
Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). (2006) (56)
Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. (2014) (55)
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. (2011) (54)
A meta-analysis of the impact of bronchial stump coverage on the risk of bronchopleural fistula after pneumonectomy. (2015) (53)
Is human hepatocellular carcinoma a hormone-responsive tumor? (2008) (50)
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. (2018) (50)
Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. (2002) (50)
Real-World Evidence in Oncology: Opportunities and Limitations. (2019) (50)
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions (2018) (50)
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. (2015) (48)
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer (2011) (48)
Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 (2018) (47)
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. (2017) (47)
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. (2021) (47)
Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study (2012) (46)
Gefitinib in Non Small Cell Lung Cancer (2011) (46)
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. (2019) (44)
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. (2013) (44)
Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. (2017) (43)
Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. (2005) (42)
Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. (2013) (40)
Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. (2016) (40)
Outcomes of First‐Generation EGFR‐TKIs Against Non‐Small‐Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE‐POSITIVE Study (2018) (40)
Targeted therapies: Role of sorafenib in HCC patients with compromised liver function (2009) (39)
Cetuximab in non-small-cell lung cancer (2012) (39)
The prognostic nutritional index predicts survival and response to first‐line chemotherapy in advanced biliary cancer (2019) (38)
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience (2005) (38)
Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. (2019) (37)
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. (2013) (37)
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. (2018) (36)
The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. (2022) (35)
Wasting lives: The effects of toxic waste exposure on health. The case of Campania, Southern Italy (2011) (35)
Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials (2020) (34)
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group (2007) (33)
Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression (2017) (33)
Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. (2012) (33)
Methodological aspects of lung cancer clinical trials in the era of targeted agents. (2010) (32)
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial) (2014) (32)
Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma (2007) (32)
COVID-19 Emergency and the Need to Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice. (2020) (32)
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. (2017) (32)
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. (2009) (31)
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. (2020) (31)
Hormonal Treatment of Human Hepatocellular Carcinoma (2006) (31)
Hormonal treatment and quality of life of prostate cancer patients: new evidence. (2018) (30)
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. (2018) (30)
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. (2014) (30)
Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. (2003) (29)
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer (2005) (29)
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. (2010) (29)
Respiratory morbidity of preterm infants of less than 33 weeks gestation without bronchopulmonary dysplasia: a 12-month follow-up of the CASTOR study cohort (2013) (29)
Coronavirus: Older Persons With Cancer in Italy in the COVID-19 Pandemic (2020) (29)
Vandetanib: An overview of its clinical development in NSCLC and other tumors. (2010) (29)
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. (2020) (29)
The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. (2004) (28)
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. (2011) (28)
Supportive care in patients with advanced non-small-cell lung cancer (2003) (28)
Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer? (2009) (28)
Implications of KRAS mutations in acquired resistance to treatment in NSCLC (2015) (28)
Second-line treatment options in hepatocellular carcinoma (2019) (28)
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial (2006) (28)
Methodology of clinical trials with new molecular-targeted agents: where do we stand? (2006) (27)
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer (2020) (27)
Maintenance therapy in NSCLC: why? To whom? Which agent? (2011) (27)
Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. (2007) (26)
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. (2019) (25)
Statistical design in phase II clinical trials and its application in breast cancer. (2003) (24)
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005 (2009) (24)
Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study (2011) (24)
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma. (2018) (24)
Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak (2020) (24)
Targeting targeted agents: open issues for clinical trial design (2009) (24)
Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel (2017) (23)
Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. (2019) (23)
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial (2006) (23)
Time Spent for Activation of Non-Profit Studies in Oncology in Italy (2010) (23)
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. (2007) (23)
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer (2012) (22)
Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). (2004) (22)
Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. (2019) (22)
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer. (2014) (22)
Trans‐arterial chemo‐embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database (2014) (21)
State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough. (2019) (21)
Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients (2012) (21)
Loss of hMSH2 expression in primary breast cancer with p53 alterations. (2004) (21)
Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma (2006) (20)
The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients’ quality of life (2019) (20)
Neuroendocrine breast carcinoma: a rare but challenging entity (2020) (20)
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial (2022) (20)
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab (2021) (20)
Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. (2012) (19)
Retrospective Multicenter Study Investigating the Role of Targeted Next‐Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung (2016) (19)
Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion (2020) (18)
The Shifting Landscape of Genitourinary Oncology During the COVID-19 Pandemic and how Italian Oncologists Reacted: Results from a National Survey (2020) (18)
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? (2016) (18)
Treatment of Patients With Metastatic Colorectal Cancer in a Real‐World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit (2017) (18)
Re: Design and endpoints of clinical trials in hepatocellular carcinoma. (2008) (18)
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. (2021) (18)
CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer (2019) (17)
Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. (2020) (17)
Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors (2013) (17)
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study (2021) (17)
Bevacizumab in non small cell lung cancer: development, current status and issues. (2012) (17)
Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence (2020) (16)
Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis. (2018) (16)
The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. (2006) (16)
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. (2014) (16)
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. (2015) (16)
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis (2021) (16)
Conventional chemotherapy of advanced pancreatic cancer. (2012) (16)
Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel. (2012) (15)
LUX-Lung: determining the best EGFR inhibitor in NSCLC? (2015) (15)
Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. (2018) (15)
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. (2012) (15)
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program (2021) (15)
Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. (2018) (15)
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. (2020) (15)
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer (2019) (15)
Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future research (2019) (15)
A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study. (2009) (14)
Impact of primary tumor location on patterns of recurrence and survival of patients undergoing resection of liver metastases from colon cancer. (2020) (14)
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. (2020) (14)
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC (2016) (14)
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. (2018) (14)
Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. (2002) (14)
Is Gemcitabine plus Vinorelbine Active in Second-Line Chemotherapy of Metastatic Breast Cancer? A Single-Center Phase 2 Study (2003) (14)
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial (2011) (14)
An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer. (2003) (14)
The burden of breast cancer in Italy: mastectomies and quadrantectomies performed between 2001 and 2008 based on nationwide hospital discharge records (2012) (14)
Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more? (2004) (14)
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG (2020) (13)
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. (2021) (13)
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives (2013) (13)
Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non–Small‐cell Lung Cancer: A Systematic Review and Meta‐analysis (2017) (13)
New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development (2010) (13)
Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. (2019) (13)
Triplet repeat instability correlates with dinucleotide instability in primary breast cancer. (2007) (13)
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. (2016) (13)
A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. (2018) (13)
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2) (2021) (13)
Vinorelbine for non-small cell lung cancer (2010) (13)
Prospective clinical trials of biotherapies in solid tumors: a 5-year survey (2004) (13)
Differences in the Availability of New Anti-Cancer Drugs for Italian Patients Treated in Different Regions. Results of Analysis Conducted by the Italian Society of Medical Oncology (AIOM) (2010) (13)
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. (2021) (12)
Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real‐world Analysis (2018) (12)
Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma (2016) (11)
Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review). (2014) (11)
Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer. (2002) (11)
FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials. (2020) (11)
Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives (2017) (11)
Outcomes research: Integrating PROs into the clinic — overall survival benefit or not, it's worth the trouble (2017) (11)
Interplay between membrane lipid peroxidation, transglutaminase activity, and Cyclooxygenase 2 expression in the tissue adjoining to breast cancer (2012) (11)
Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials (2005) (11)
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab (2022) (11)
Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors (2019) (11)
153Sm: its use in multiple myeloma and report of a clinical experience. (2008) (11)
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial (2009) (10)
Successful implementation of infection control measure in a neonatal intensive care unit to combat the spread of pathogenic multidrug resistant Staphylococcus capitis (2019) (10)
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors (2022) (10)
Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy? (2006) (10)
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer (2017) (10)
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis (2021) (10)
Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol (2019) (10)
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis (2016) (10)
Significance of erb-B2 immunoreactivity in cervical cancer. (2006) (10)
Clinical and Organizational Issues in the Management of Surviving Breast and Colorectal Cancer Patients: Attitudes and Feelings of Medical Oncologists (2014) (9)
Single agent vs combination chemotherapy (CT) as second-line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data of five randomized trials (2008) (9)
A survey on physicians’ knowledge, practice and attitudes on fertility and pregnancy issues in young breast cancer patients (2017) (9)
Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments (2020) (9)
p53 Expression is Decreased in Primary Breast Carcinomas with Microsatellite Instability (2002) (9)
153Sm: its use in multiple myeloma and report of a clinical experience (2008) (9)
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies (2022) (9)
Lessons from clinical trials on quality-of-life assessment in ovarian cancer trials. (2016) (9)
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation (2021) (9)
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. (2022) (9)
Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study (2020) (9)
Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. (2019) (9)
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). (2013) (9)
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. (2020) (9)
Granulomatous Lobular Mastitis: Another Manifestation of Systemic Lupus Erythematosus? (2013) (9)
Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro? (2004) (8)
New biological treatments for gynecological tumors: focus on angiogenesis (2014) (8)
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study (2021) (8)
Impact of Blinding on Patient-Reported Outcome Differences between Treatment Arms in Cancer Randomized Controlled Trials. (2021) (8)
Rationale and Design of MILES-3 and MILES-4 Studies : Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non e Small-Cell Lung Cancer (8)
Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. (2011) (8)
The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial (2010) (8)
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system (2021) (8)
The ICET-A Survey on Current Criteria Used by Clinicians for the Assessment of Central Adrenal Insufficiency in Thalassemia: Analysis of Results and Recommendations (2016) (8)
Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide (2018) (8)
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM) (2020) (8)
Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review (2020) (8)
Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy (2016) (8)
BRAF-mutated metastatic colorectal cancer between past and future (2015) (8)
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. (2020) (8)
Patients’ Attitudes and Physicians’ Perceptions Toward Maintenance Therapy for Advanced Non–Small‐cell Lung Cancer: A Multicenter Italian Survey (2017) (7)
Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature (2015) (7)
Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review. (2019) (7)
Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better…. (2014) (7)
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial. (2017) (7)
Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice? (2007) (7)
COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave? (2021) (7)
Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence (2011) (7)
Comment on: Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. Authors' reply (2008) (7)
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders. (2020) (7)
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. (2020) (7)
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside (2022) (7)
Treatment of small cell lung cancer. (2014) (7)
A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future (2021) (7)
Prophylactic cranial irradiation in extensive disease small cell lung cancer: An endless debate. (2019) (7)
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index (2021) (6)
Predictivity of clinical, laboratory and imaging findings in diagnostic definition of palpable thyroid nodules. A multicenter prospective study (2018) (6)
Integrated therapeutic approaches in the treatment of locally advanced non-small cell lung cancer. (2013) (6)
Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma? (2017) (6)
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). (2011) (6)
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review. (2022) (6)
Subgroup Analysis: Refining a Positive Result or Trying to Rescue a Negative One? (2015) (6)
Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET.... (2015) (6)
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients (2022) (6)
Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. (2021) (6)
Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial (2012) (6)
An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer. (2017) (6)
Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM) (2018) (6)
Complete resolution of psoriasis in a patient treated with stealth liposomal doxorubicin and carboplatin for ovarian cancer (2004) (6)
Medical treatment of resistant or recurrent epithelial ovarian cancer. (2006) (6)
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. (2012) (6)
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. (2021) (5)
Target therapy for hepatocellular carcinoma: is sorafenib for everybody? (2009) (5)
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study (2019) (5)
Immunotherapy in advanced anal cancer: Is the beginning of a new era? (2022) (5)
The impact of decreasing cutoff values for maximal oxygen consumption (VO(2)max) in the decision-making process for candidates to lung cancer surgery. (2013) (5)
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. (2017) (5)
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system (2020) (5)
Corrigendum to 'is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery?' [Eur J Cardiothorac Surg 2011;40: 912-18] (2012) (5)
Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study (2021) (5)
In reply [8] (2005) (5)
Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment? (2018) (5)
Neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC) with or without oxaliplatin (OX): Individual patient data (IPD) meta-analysis of three randomized controlled trials (RCTs) with subgroup analyses of age cohorts. (2020) (5)
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (2018) (5)
Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). (2020) (5)
Time trend in treatment-related deaths of patients with advanced non-small cell lung cancer enrolled into phase III trials of systemic treatment. (2010) (5)
Quality of life: an important element of treatment value. (2017) (5)
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer (2017) (5)
Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All Approach. (2019) (5)
Factorial design for randomized clinical trials. (2006) (5)
Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis (2021) (5)
Prognostic score for second-line chemotherapy of advanced non-small cell lung cancer (NSCLC): External validation in a phase III trial comparing vinflunine with docetaxel. (2011) (5)
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. (2020) (5)
Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions. (2016) (4)
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: an individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature (2021) (4)
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). (2011) (4)
Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review (2018) (4)
Quality of life in patients with lung cancer: the way forward. (2020) (4)
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study. (2021) (4)
OA07.07 Quality of Life (QoL) Analysis in Lung Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2018 (2019) (4)
Ethics in Oncology: Principles and Responsibilities Declared in the Italian Ragusa Statement (2016) (4)
Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control. (2013) (4)
Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study. (2019) (4)
New emerging targets in advanced urothelial carcinoma: is it the primetime for personalized medicine? (2022) (4)
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) (2022) (4)
The Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology Meetings. (2020) (4)
Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy (2016) (4)
Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016. (2019) (4)
[Excisional biopsy with wire localisation of non-palpable breast lesions: indications and limitations]. (2005) (4)
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. (2015) (4)
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study (2021) (4)
Subhepatic neonatal appendicitis in premature babies: First case detected by ultrasound. (2015) (4)
COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC). (2011) (4)
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. (2016) (4)
Capecitabine plus temozolomide in well or moderately differentiated primary atypical neuroendocrine tumors: a single centre experience of two cases. (2018) (4)
Accuracy of Dose Administered to Children Using Off-Labelled or Unlicensed Oral Dosage Forms (2021) (4)
Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased? (2009) (4)
Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter? (2008) (4)
Isolated neonatal bilateral vocal cord paralysis revealing a unilateral medullary defect: a case report (2018) (4)
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience (2020) (4)
Carboplatin plus paclitaxel scheduling for advanced ovarian cancer - authors' reply. (2014) (4)
Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study. (2017) (3)
Impact of adoption of patient-reported outcomes in clinical practice on the accuracy of symptom reporting in medical records of cancer patients. (2020) (3)
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients (2017) (3)
Palonosetron: more than just another option? (2009) (3)
Indication for Venous Ports in Oncology Comparing Different Experiences in Europe (2001) (3)
Oncomovies: Cancer in Cinema (2012) (3)
[Very preterm birth less than 33 weeks' gestation: how setting-up of a perinatal network does influence the activity of the neonatal tertiary care unit? The experience of the Poitou-Charentes region, France]. (2007) (3)
Bone effects of adjuvant tamoxifen (T), letrozole (L), or L plus zoledronic acid (Z) in early breast cancer (EBC): The phase III HOBOE study. (2011) (3)
Residual neurotoxicity in patients with ovarian cancer in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trials in Ovarian cancer (MITO-4) retrospective study (2005) (3)
AISF position paper on HCV in immunocompromised patients (2019) (3)
Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the “BRAF, BeCool” platform. (2018) (3)
Single Nucleotide Polymorphisms in Cancer Research and Treatment (2019) (3)
P2.04-15 Association Between Opioids and Outcome of 1st Line Immunotherapy in Advanced NSCLC Patients: A Retrospective Evaluation (2019) (3)
Two-drug gemcitabine-based first-line treatment of elderly patients (pts) with small cell lung cancer (SCLC): The G-STEP program. (2006) (3)
Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): A network meta-analysis of randomized controlled trials (RCT) (2019) (3)
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate (2021) (3)
Chemotherapy‐Induced Neutropenia and Outcome in Patients With Metastatic Castration‐Resistant Prostate Cancer Treated With First‐Line Docetaxel (2018) (3)
Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves. (2021) (3)
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers (2022) (3)
Neonatal outcomes for women at risk of preterm delivery given half dose versus full dose of antenatal betamethasone: a randomised, multicentre, double-blind, placebo-controlled, non-inferiority trial (2022) (3)
Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study). (2020) (3)
Randomized phase II study of niraparib plus best supportive care (BSC) versus BSC alone as maintenance treatment in patients with advanced urothelial carcinoma (UC) whose disease did not progress after first-line platinum-based chemotherapy (PBCT): The Meet-URO12 trial. (2022) (3)
Disparity in the “time to patient access” to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM) (2011) (3)
Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer. (2016) (3)
Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations (2021) (3)
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. (2021) (3)
Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM) (2016) (3)
[Rubella in pregnancy. Management and prevention]. (1999) (3)
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials (2021) (3)
Bone-targeted therapy in castration-resistant prostate cancer: where do we stand? (2019) (3)
[Cancer on the big screen. How and when movies deal with oncological diseases]. (2014) (2)
MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study. (2018) (2)
Heterogeneity of treatment effects in malignant pleural mesothelioma (2021) (2)
How are cared surviving cancer patients? Results of an Italian national survey to medical oncologists (MO) about clinical and organizational features of follow-up (FU). (2012) (2)
167P Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 6 randomized trials (2021) (2)
Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study. (2017) (2)
A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study. (2012) (2)
Measuring financial toxicity of cancer in the Italian health care system: Initial results of the patient reported outcome for fighting financial toxicity of cancer project (proFFiT) (2019) (2)
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis (2022) (2)
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis (2017) (2)
Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials (2012) (2)
Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). (2013) (2)
Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018. (2019) (2)
Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis. (2020) (2)
OSTEONECROSIS OF THE JAW (ONJ) IN CANCER AND MYELOMA PATIENTS. A 16-YEAR EXPERIENCE OF “RETE ONCOLOGICA PIEMONTE–VALLE D’AOSTA” CANCER NETWORK (2021) (2)
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis (2022) (2)
[Linear IgA bullous dermatosis in children with autoantibodies against 180 kDa pemphigoid antigen]. (1996) (2)
Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802). (2018) (2)
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) (2021) (2)
Survey of modalities of assessing and reporting toxicity in non-comparative prospective studies of chemotherapy in breast cancer (2001) (2)
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations (2022) (2)
Equity in Drug Accessibility: The Surprising Case of Treatments for Metastatic Castration-sensitive Prostate Cancer in European Countries. (2021) (2)
Selection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase Inhibitors (2017) (2)
[Enuresis and benign micturition disorders in childhood. I. Diagnosis and management]. (1995) (2)
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with Abiraterone or Enzalutamide. (2021) (2)
Capecitabine (CAP) versus 5-fluorouracil (FU) in combination with oxaliplatin (OX) as 1st-line chemotherapy (CT) for advanced colorectal cancer (ACRC): Meta-analysis of randomized clinical trials (RCT) (2008) (2)
QoL is a cool tool. (2017) (2)
[Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy]. (2008) (2)
The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer. (2015) (2)
Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study. (2022) (2)
Second medical opinion in oncological setting. (2021) (2)
Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? (2018) (2)
Early onset metastatic colorectal cancer in patients receiving panitumumab‐based upfront strategy: Overall and sex‐specific outcomes in the Valentino trial (2022) (2)
A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step? (2021) (2)
Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey (2022) (2)
Comments on “Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)” (2022) (2)
What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities (2016) (2)
Luteinized thecoma (thecomatosis) with sclerosing peritonitis: a systematic review of the literature of the last 25 years (2020) (2)
Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. (2020) (1)
1700P Perception and attitudes of Italian physicians towards the management of checkpoint inhibitors in oncology during COVID-19 outbreak: Results from a national survey (2020) (1)
B06Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study (2016) (1)
Post-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO). (2018) (1)
A multicenter, retrospective study on impact of immunotherapy in urothelial carcinoma with bone metastases (Meet-Uro01 Study). (2021) (1)
256OWEEKLY DOCETAXEL (WD) VS CMF AS ADJUVANT CHEMOTHERAPY FOR ELDERLY EARLY BREAST CANCER (EBC) PATIENTS (PTS): FINAL RESULTS FROM THE RANDOMISED PHASE 3 ELDA TRIAL. (2014) (1)
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis. (2022) (1)
Advanced hepatocellular carcinoma: Impact of systemic treatments on health‐related quality of life and patient‐reported outcomes (2022) (1)
Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study. (2019) (1)
Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy (2016) (1)
Endoscopic surveillance for hereditary non-polyposis colorectal cancer (HNPCC) family members in a Southern Italian region. (2010) (1)
Prescription of Aminoglycosides in 23 French Neonatal Intensive Care Units (2021) (1)
Trends in exposure to multiple lines of treatment and survival of patients with metastatic renal cell carcinoma: A real-world analysis. (2017) (1)
Resveratrol Plus Simvastatin Are Effective in Decreasing IgM Secretion in Asymptomatic Waldenstrom Macroglobulinemia. One Year Follow-up. (2009) (1)
Prognostic evaluation and choice of second-line treatment for patients with advanced non-small-cell lung cancer (2012) (1)
1030 TRANS-ARTERIAL CHEMO-EMBOLIZATION (TACE) IS SAFE AND EFFICIENT FOR ELDERLY PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC): RESULTS FROM AN INTERNATIONAL META-DATABASE (2012) (1)
Expected survival of cancer patients and myeloma undergoing bisphosphonates or denosumab. Potential impact on diagnosis and management of Osteonecrosis of Jaws (ONJ) (2021) (1)
Quality of life: an important element of treatment value (2017) (1)
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status (2022) (1)
Setting the standard for advanced pancreatic ductal adenocarcinoma (A-PDAC) in 2010: Meta-regression and power analysis of phase III randomized clinical trials (RCT) evaluating gemcitabine (GEM) in combination with cisplatin (CIS), oxaliplatin (L-OHP), or capecitabine (CAP). (2010) (1)
Hurrying up but not rushing, acting and not reacting, good sense and not common sense: Open thoughts and reasonable doubts on COVID-19 vaccination strategies in cancer patients (2021) (1)
Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study). (2020) (1)
P1.13-16 The Diagnostic Accuracy of Circulating Tumor DNA for the Detection of EGFR-T790M Mutation in NSCLC: A Systematic Review and Meta-Analysis (2018) (1)
Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis. (2017) (1)
Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. (2020) (1)
Pancreatic Involvement from Heavily Pretreated Small Cell Lung Cancer Successfully Treated with Transcatheter Intra-Arterial Chemotherapy: A Case Report with Local and Systemic Disease Control (2002) (1)
800TiP Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy (2020) (1)
Efficacy and tolerability of pregabalin in the management of pain associated with administration of high-dose imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CML) (2008) (1)
Registrative trials of antiemetic drugs: arrival or starting point? (2009) (1)
Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial. (2023) (1)
Can intercalating chemotherapy with epidermal growth factor receptor inhibitors delay development of treatment resistance in advanced non-small cell lung cancer? (2017) (1)
1740P Assessing the impact of COVID-19 outbreak on the attitudes and practice of Italian oncologists towards breast cancer care and related research activities (2020) (1)
Incidence and pathological characteristics of prostate cancer in Italy: a contribution to the screening debate. (2006) (1)
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study (2023) (1)
Oncology and public health (2012) (1)
Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC). (2013) (1)
EGFR FASTnet: The Italian network for epidermal growth factor receptors (EGFR) mutation analysis in non-small cell lung cancer (NSCLC). (2011) (1)
Procalcitonin can Fail to Rise in Severe Bacterial Infections 69 (1996) (1)
Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial (2022) (1)
Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias? (2017) (1)
215PEXPRESSION OF AXL RECEPTOR AND ITS LIGAND GAS6 IN COLORECTAL CANCER (CRC). (2014) (1)
Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology: Beyond Citation Counts. (2016) (1)
LUX-Lung 7: is there enough data for a final conclusion? (2016) (1)
Correction to: Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments (2020) (1)
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences. (2022) (1)
A multicenter, randomised, phase III trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in advanced SCLC patients. The STAD-1 trial. (2015) (1)
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21). (2021) (1)
C17Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: PRO-BMI study (2016) (1)
1480OSYMPTOMATIC TOXICITIES EXPERIENCED DURING ANTI-CANCER TREATMENT: COMPARISON OF PATIENTS' AND PHYSICIANS' REPORTING IN THREE RANDOMIZED CONTROLLED TRIALS (RCTS). (2014) (1)
MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression (2018) (1)
Education level as prognostic factor of patients (pts) with advanced non-small cell lung cancer (NSCLC) enrolled in clinical trials. (2010) (1)
Luminal-like HER 2-negative stage IA breast cancer : a multicenter retrospective study on long-term outcome with propensity score analysis (2017) (1)
Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report (2019) (1)
IMPACT OF DIFFERENT DOSING STRATEGIES OF NIVOLUMAB IN PATIENTS WITH SOLID TUMORS: ITALIAN SINGLE CENTER ANALYSIS (2021) (1)
Frequency and clinical correlations of epidermal growth factor receptor (EGFR) mutations in a large cohort of Italian non-small cell lung cancer (NSCLC) patients (pts) within the EGFR FASTnet program. (2012) (1)
Cetuximab for metastatic colorectal cancer. (2009) (1)
Implementing clinical trials in oncology with quality of life assessment and patient reported outcomes. An interview to explore the road towards a more patient-centered approach (2021) (1)
Impact of use of Oral Anticancer Drugs on Activity of Italian Oncology Practices: Results of a Survey Conducted by the Italian Society of Medical Oncology (AIOM) (2013) (1)
Long term control of luteinized thecoma with sclerosing peritonitis with leuprorelin and tamoxifen treatment (2019) (1)
CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer (2019) (1)
A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice. (2017) (1)
Intercalated combination of chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non-small-cell lung cancer: A systematic review and meta-analysis (2016) (1)
Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer (2011) (1)
The economic burden of chemotherapy-induced nausea and vomiting and its impact on the quality of life of Italian cancer patients. (2004) (1)
P2.14-14 Comparison of Molecular Testing Modalities for Detection of NRG1 Rearrangements in Invasive Mucinous Adenocarcinoma (2019) (1)
MET exon 14 mutation: another actionable genomic variation in patients with advanced NSCLC (2016) (1)
Health-related quality of life in recurrent platinum-sensitive ovarian cancer — results from the CALYPSO trial (0)
Reply to the letter to the editor 'On the underreporting of health-related quality of life and regulatory approval' by Bhamidipati et al. (2019) (0)
[Bacterial meningitis as a complication of central nervous system malformations]. (2009) (0)
[Neonates exposure to parabens through medicines administered to inpatients]. (2020) (0)
Reply to the letter to the editor 'On the underreporting of health-related quality of life and regulatory approval' by Bhamidipati et al. (2019) (0)
[Hypertrophic gastritis and cytomegalovirus infection]. (1996) (0)
Prognostic factors in patients enrolled in clinical trials of second-line chemotherapy for advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 11 randomized trials. (2009) (0)
Single Nucleotide Polymorphisms in Cancer Research and Treatment (2019) (0)
Clinical value of offering multiple chemotherapy lines to a luminal-like metastatic breast cancer: A case report with eribulin. (2022) (0)
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial (2023) (0)
[Let's go forward, but wisely…]. (2017) (0)
Zoledronic Acid Dosing Interval for Metastatic Cancer. (2017) (0)
Chemotherapy and immunotherapy in metastatic colorectal cancer. (2009) (0)
Elderly cancer patients: our future? (2002) (0)
Correlation of PD-L1 staining between primitive tumor and metastasis in advanced colorectal cancer patients. (2017) (0)
Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER). (2023) (0)
Correlation of pd-l1 staining in tumor cells and tumor infiltrate between primary tumors and matched metastasis in advanced colorectal cancer patients. (2017) (0)
1755P The beginning of the COVID-19 era: The perception of oncological patients (pts) in active treatment at the Brindisi and Mauriziano Hospital Oncology Departments (2020) (0)
1616P Drop in early-stage colorectal cancer diagnoses after COVID-19: Preliminary report from the COVID-DELAY study (2021) (0)
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society. (2023) (0)
[Could a medication management app help people to optimize their oral cancer drugs intake?] (2020) (0)
Reply to P. Baldo et al. (2015) (0)
The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer (2020) (0)
Immune-checkpoint inhibitors in previously treated patients with urothelial carcinoma: A systematic review and meta-analysis. (2018) (0)
[Influenza vaccination in advanced cancer patients undergoing immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: what data do we have for the clinical recommendation?] (2018) (0)
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. (2022) (0)
Physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey. (2018) (0)
Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy. (2023) (0)
P59.20 Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study (2021) (0)
Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer? (2018) (0)
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study (2023) (0)
[Thoughts on current management of severe neonatal hyperbilirubinemia]. (2002) (0)
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial) (2014) (0)
The value of patient-reported outcomes in single-arm cancer trials. (2023) (0)
[Outcomes reported by the patient: a tool for respecting the patient's rights and for involvement in research.] (2020) (0)
[Description of adverse events in publications of clinical trials: much room for improvement.] (2019) (0)
Chemotherapy with immune-checkpoint inhibitors in first-line treatment metastatic NSCLC patients: Systematic review and literature-based meta-analysis. (2019) (0)
1250PEPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND ABCG2 POLYMORPHISMS AND TREATMENT OUTCOME IN THE RANDOMIZED PHASE III TORCH TRIAL IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS. (2014) (0)
ADOPTION OF PATIENT-REPORTED OUTCOMES IN CLINICAL PRACTICE FOR OLDER PATIENTS RECEIVING ACTIVE ANTI-CANCER TREATMENT: IMPACT ON HEALTH-RELATED QUALITY OF LIFE (2021) (0)
1249PCMET EXPRESSION AND ACTIVITY OF FIRST-LINE ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): EXPLORATORY ANALYSIS OF THE RANDOMIZED PHASE III TORCH TRIAL. (2014) (0)
BOOST: a phase 3 trial of sorafenib vs. best supportive care in first line treatment of hepatocellular carcinoma in patients with deteriorated liver function (2021) (0)
1626P Time trends (2012-2016 vs 2017-2021) in health-related quality of life (QoL) assessment and reporting in oncology: A systematic review of randomized phase III trials (2022) (0)
[Objectives of clinical experimentation in carcinoma of the lung]. (2004) (0)
A multicenter randomized phase 4 trial comparing sodium picosulphate plus magnesium citrate vs. polyethylene glycol plus ascorbic acid for bowel preparation before colonoscopy. The PRECOL trial (2022) (0)
Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis. (2022) (0)
Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors (2023) (0)
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy (2022) (0)
Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. (2021) (0)
P45.12 Renal Function Change During Alectinib in ALK Rearranged Non-Small Cell Lung Cancer: A Retrospective Multicentre Analysis (2021) (0)
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. (2023) (0)
Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis (2023) (0)
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap (2022) (0)
Clinical Trials and Methodology of Cancer Research (2021) (0)
Efficiency of Continuous Subcutaneous Insulin Infusion for Premature Neonate: A Case Report (2022) (0)
[Recurrent acute intestinal intussusception]. (1995) (0)
Carcinoid heart failure in a duodenal neuroendocrine tumor: role of cardiac surgery in a challenging patient and brief review of the literature (2020) (0)
Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature (2015) (0)
[Management of hyperbilirubinemia of the term newborn in maternity wards]. (1998) (0)
Differences in the Availability of New Anti-Cancer Drugs for Italian Patients Treated in Different Regions. Results of Analysis Conducted by the Italian Society of Medical Oncology (AIOM) (2010) (0)
1444P Cancer diagnosis communication: The perspective of oncologists, patients and caregivers (2022) (0)
[Haemophilus influenzae meningitis following vaccination. Consequence or coincidence?]. (1996) (0)
Pre-existing evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review. (2023) (0)
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. (2023) (0)
50P Direct-acting oral anticoagulants prescribing pattern in patients with gynaecological cancer: Results of a survey among Italian oncologists belonging to MITO group and AIOM society (2022) (0)
Therapeutic sequencing in advanced renal cell carcinoma: how to choose considering clinical and biological factors. (2022) (0)
Insert: Therapeutic Operative Procedures Suggested by an Expert: From Clinical Trials to Clinical Practice (2019) (0)
1497P Cancer patients’ awareness about clinical research: The ELPIS study preliminary results (2021) (0)
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience (2023) (0)
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer (2022) (0)
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (2018) (0)
Single Agents or Combination Chemotherapy for Advanced Ovarian Carcinoma in Elderly Patients: Pro Single Agents (2002) (0)
Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study. (2022) (0)
A multicentre, prospective phase 2 study of weekly schedule of carboplatin (C) plus paclitaxel (P) in first-line treatment of elderly patients (pts) with ovarian cancer (OC). The MITO (Multicentre Italian Trials in Ovarian cancer)-5 study. (2016) (0)
[Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).] (2021) (0)
Adjuvant therapy and outcomes in patients with stage IA breast cancer. (2015) (0)
Response to : Comment on ‘ Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma ' (2015) (0)
Subject Index Vol. 64, 2003 (2003) (0)
CMAR_A_216220 3721..3729 (2020) (0)
LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study. (2021) (0)
11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study (2020) (0)
Abiraterone's effi cacy confi rmed; time to aim higher (2015) (0)
PRO-BMI study: prognostic role of body mass index (BMI) in metastatic castration resistant prostate cancer (mCRPC) patients receiving chemotherapy. (2016) (0)
Breast surgery and new adhesives: our experience (2005) (0)
Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting (2017) (0)
Supportive Care Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting (2018) (0)
The role of meta-analysis in defining clinical practice in advanced non-small-cell lung cancer (2013) (0)
1554PEfficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting in patients receiving carboplatin-based chemotherapy (2017) (0)
Chronic and late-onset toxicities from immune checkpoints inhibitors (ICIs): Analysis of the publications leading to ICIs approval between 2011 and 2019 (2019) (0)
Romiplostim Treatment Mimicking Cyclic Thrombocytopenia In 3 Patients with Chronic Idiopatic Thrombocytopenic Purpura (2010) (0)
Pharmacological bioquivalence of branded and generic oxaliplatin: from preclinical assessment to clinical incidence of hypersensitivity reactions in patients with colorectal cancer (2016) (0)
Hospitalization for bronchiolitis in very preterm infants without broncho-pulmonary dysplasia (2011) (0)
ecent issues in first-line treatment of advanced non-small-cell lung cancer : esults of an International Expert Panel Meeting of the Italian Association of horacic (2009) (0)
Is oral therapy a real advantage? Contra (2003) (0)
A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM) (2019) (0)
Epidermal Growth Factor Receptor Mutations in Italian Non-Small-Cell Lung Cancer Patients Enrolled in the EGFR Fastnet Program (2012) (0)
Endocrine effects of aromatase inhibitors as adjuvant treatment in postmenopausal breast cancer patients (2011) (0)
Predictive role of clinical benefit (CB) at 1st line on the outcome of subsequent lines in metastatic breast cancer (MBC) patients: analysis of a “real life” population. (2016) (0)
LATITUDE and other coordinates in quality of life of prostate cancer patients (2018) (0)
674P Evaluation of cognitive function (CogF) in trials testing new-generation hormonal treatments (NGHT) in patients with prostate cancer (PC): A systematic review (2020) (0)
Afatinib in advanced non-small-cell lung cancer (2013) (0)
117P Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients (2021) (0)
REP Regimen (Rituximab, Erythropoietin and Prednisone) in the Treatment of Refractory Autoimmune Hemolytic Anemia (R-AIHA). (2008) (0)
P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC) (2018) (0)
1783P Multi-parametric T cells profiling in broncho-alveolar lavage fluid (BAL) and blood from advanced lung cancer patients (2021) (0)
970O CARBOPLATIN PLUS PACLITAXEL VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN AS FIRST- LINE TREATMENT FOR PATIENTS WITH OVARIAN CANCER: THE MITO-2 (MULTICENTRE ITALIAN TRIALS IN OVARIAN CANCER) RANDOMIZED PHASE III TRIAL (2010) (0)
Moving from the CLEOPATRA study to real life: Results from the G.O.N.O. SUPER trial. (2018) (0)
56 CISPLATIN VERSUS CARBOPLATIN-BASED REGIMENS IN THE FIRST-LINE TREATMENT OF SMALL CELL LUNG CANCER (SCLC): META-ANALYSIS OF PUBLISHED RANDOMIZED CLINICAL TRIALS (RCTS) (2010) (0)
A17First line treatment in patients with luminal-like metastatic breast cancer: a propensity score-matched analysis (2015) (0)
Quality of life results: a fine dowel in the mosaic of treatment value. (2019) (0)
140P Prognostic and predictive value of co-mutational profile in advanced EGFR positive NSCLC patients treated with TKIs (2021) (0)
Statistical design in published non-comparative prospective studies of chemotherapy in breast cancer (2001) (0)
Patient-reported outcomes in the evaluation of toxicity of anticancer treatment (0)
Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer. (2011) (0)
Efficacy and Tolerability of Pregabalin in Decreasing Pain Associated with High Dose of Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase CML. (2007) (0)
763P Treatment response to non-platinum therapies in ovarian cancer patients according to BRCA status: A retrospective analysis of a large multicentric cohort (2021) (0)
A11Molecular profiling in advanced non-small-cell lung cancer: preliminary data of the Italian observational prospective study (2016) (0)
Activity of eribulin on skin metastases in breast cancer patients. (2013) (0)
D25Treatment of patients with metastatic colorectal cancer in a real-word scenario: probability of being submitted and clinical benefit of second and further lines of therapy (2016) (0)
The DISTAL-2 phase III randomized trial of single agent weekly docetaxel (wD) vs wD plus gemcitabine (G) or vinorelbine (V) vs wD plus capecitabine (X) as second-line treatment of advanced non-small-cell lung cancer (NSCLC) patients (pts) (2008) (0)
Abstract LB-256: Impact of metformin on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNETs) receiving everolimus and/or somatostatin analogues: A sensitivity analysis of the PRIME-NET (pancreatic multicentric, retrospective, italian metformin) study (2017) (0)
Host metabolic factors and prognosis in patients treated with immune checkpoint inhibitors for advanced malignancies. (2019) (0)
Afatinib in advanced non-small-cell (2013) (0)
Locoregional and systemic treatments for patients with hepatocellular carcinoma (2009) (0)
Local recurrence in women with ductal carcinoma in situ (DCIS) according to the treatment (1998) (0)
C04Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel (2016) (0)
F29Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration- resistant prostate cancer (mCRPC): an exploratory analysis (2015) (0)
Contents Vol. 64, 2003 (2003) (0)
Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer (2019) (0)
A randomized clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL (Docetaxel in Second-Line Treatment of Advanced Lung Cancer) (2004) (0)
D49Phase ii study of mytomicin-c plus uft/lv in patients with metastatic colorectal cancer refractory to standard chemotherapy. subgroup analysis of predictive variables in discriminating early progressors (2016) (0)
Prognostic score for second or further line immunotherapy in advanced non-small cell lung cancer (aNSCLC): An external validation. (2019) (0)
F22Maintenance hormonal therapy (MHT) in metastatic breast cancer (MBC) patients treated with first-line chemotherapy: retrospective analysis of the impact on progression-free survival (PFS) and overall survival (OS) in a “real life” setting (2016) (0)
Adoption of patient-reported outcomes (PROs) in clinical practice for older patients receiving active anticancer treatment: Impact on health-related quality of life (QoL). (2021) (0)
Abstract 4887: RecurrentNRG1rearrangements in Caucasian pulmonary mucinous adenocarcinoma: results from an Italian multi-center cohort (2019) (0)
Could a medication management app help people to optimize their oral cancer drugs intake (2020) (0)
5047 Effects on quality of life (QoL) of docetaxel-based weekly chemotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC): results of a single-centre randomized phase 3 trial (2009) (0)
4CPS-285 Multidisciplinary oral therapy outpatient clinic: an Italian single centre experience (2021) (0)
Mo1446 Is Noncathartic Computed Tomographic Colonography With Fecal Tagging Useful for the Surveillance of Hereditary Non-Polyposis Colorectal Cancer Family Members? Preliminary Data of a Single Center Study (2012) (0)
health economicsThe effect of financial difficulties on clinical outcomes in Italian cancer patients: A pooled analysis of 16 academic prospective clinical trials (2016) (0)
Randomized phase III trial of gemcitabine and cisplatin versus gemcitabine alone in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) 2: CAPPA-2 study. (2017) (0)
Rituximab, Endoxan, Ganciclovir, Dexamethasone, Tocilizumab Sequential Treatment In Kaposi's Sarcoma-Associated Herpesvirus (KSHV) -Related Multicentric Castleman Disease. A Case Report with 8 Months Follow-up (2010) (0)
Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: A systematic review and literature-based meta-analysis. (2019) (0)
C linical P harmacology Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions (2006) (0)
H01*A multicenter, randomised, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in advanced SCLC patients (pts). The STAD-1 trial (2015) (0)
Diagnostic Gleason score and castration- resistant prostate cancer (2016) (0)
Quantitative bone ultrasonography at phalanges in patients with high-risk monoclonal gammopathy of unknown significance (MGUS) and myeloma treated with zoledronic acid (2007) (0)
Randomized phase II study of CAPTEM versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer (mCRC): Final analysis, tumour biomarkers and methylated ctDNA (2019) (0)
IMPLEMENTING CLINICAL TRIALS IN ONCOLOGY WITH QUALITY OF LIFE ASSESSMENT AND PATIENT REPORTED OUTCOMES. AN INTERVIEW TO EXPLORE THE ROAD TOWARDS A MORE PATIENT-CENTERED APPROACH (2021) (0)
Early PET/CT scan compared with RECIST to predict long-term outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. (2013) (0)
P.17.7 USEFULNESS OF NONCATHARTIC CT COLONOGRAPHY WITH FECAL TAGGING FOR THE SURVEILLANCE OF HNPCC FAMILY MEMBERS. PRELIMINARY DATA (2012) (0)
The role of ' early phases ' : are traditional phase I studies with new drugs reliable ? (2015) (0)
Abstract LB-238: Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) inRASandBRAFwild-type (wt) metastatic colorectal cancer (mCRC) (2017) (0)
Measuring financial toxicity of cancer in the Italian health care system: Initial results of the patient reported outcome for fighting financial toxicity of cancer project (proFFiT). (2019) (0)
P2.03b-063 Molecular Profiling in Advanced Non-Small-Cell Lung Cancer: Preliminary Data of an Italian Observational Prospective Study: Topic: Biomarkers (2017) (0)
P-202Preclinical assessment of the bioequivalence of branded and generic oxaliplatin and incidence of hypersensitivity reactions in patients with advanced colorectal cancer (2016) (0)
P1.14-26 ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma (2019) (0)
Efficacy and safety of afatinib in advanced non-small cell lung cancer (2013) (0)
Biases in assessment and reporting of health-related quality of life (QoL): A systematic review of oncology randomized phase III trials published between 2012 and 2016. (2018) (0)
797P Health-related quality of life (HRQoL) with pembrolizumab (pembro) monotherapy in patients (pts) with previously treated advanced microsatellite instability high (MSI-H) endometrial cancer: Results from KEYNOTE-158 (2021) (0)
D35A systematic review of the safety profile of bolus, continuous infusion of 5-fu and capecitabine in combination with oxaliplatin in the treatment of colorectal cancer patients (2016) (0)
422P Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (LARC): Individual patient data (IPD) meta-analysis of three randomised trials (RTs) (2020) (0)
1864 Chemotherapy versus endocrine therapy as first line treatment in patients with luminal-like metastatic breast cancer. Impact on survival (2015) (0)
C28Sequencing cabazitaxel and new generation hormonal treatments in metastatic castration resistant prostate cancer patients after first line docetaxel: a retrospective analysis (2016) (0)
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: Retrospective analysis of clinical outcomes. (2020) (0)
Disease-free survival (DFS) as surrogate end-point for overall survival (OS) in early breast cancer (EBC): Correlation may be different according to drugs and/or strategies tested (2008) (0)
Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): An exploratory analysis. (2015) (0)
Cancer patients’ awareness about clinical research in the era of social media and “fake news”: Preliminary results from ELPIS Study. (2021) (0)
ES19.04 Improving Lung Cancer Survival Through Tracking of Patient Reported Outcomes (2021) (0)
[Let's go forward, but wisely…]. (2017) (0)
[Outcomes reported by the patient: a tool for respecting the patient's rights and for involvement in research.] (2020) (0)
FP12.06 GRIm-Score Variations Predict Outcome in Metastatic NSCLC Patients Treated with First-Line Pembrolizumab (2021) (0)
Insert: Therapeutic Operative Procedures Suggested by an Expert: From Clinical Trials to Clinical Practice (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Massimo Di Maio?

Massimo Di Maio is affiliated with the following schools:

University of Milan
University of Verona
University of Palermo
University of Turin
University of Bologna

Massimo Di Maio's Academic­Influence.com Rankings

Massimo Di Maio's Degrees

Similar Degrees You Can Earn

Why Is Massimo Di Maio Influential?

Massimo Di Maio's Published Works

Published Works

What Schools Are Affiliated With Massimo Di Maio?

Massimo Di Maio's AcademicInfluence.com Rankings